Cancers & treatments·Regimen libraryInduction

R-ICE

Checked 2026-09-09

Relapsed or refractory DLBCL, salvage before autologous transplant (late relapse) or bridging

One cycle

every 14 days × 2-3 · about 4 weeks in total

14-day cycle × 2-3 (about 4 weeks)Intravenous Continuous infusion

Components

Drug	Dose	Route	Days
Rituximab Monoclonal antibody (anti-CD20, chimeric)	375 mg/m²	IV	D1
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative)	100 mg/m²	IV	D1-3
Carboplatin Cytotoxic chemotherapy (platinum)	AUC 5 (maximum 800 mg)	IV	D2
Ifosfamide Cytotoxic chemotherapy (alkylating agent)	5,000 mg/m² with mesna	IV	D2 (24 h infusion)

Cycles

2-3

14-day cycle

Emetogenicity

High (>90%)

G-CSF

Built into the protocol

Notes

ZUMA-7 and TRANSFORM: CAR-T beats salvage chemotherapy plus transplant for early relapse (within 12 months).

Used in

Diffuse large B-cell lymphoma

Trials

ZUMA-7 TRANSFORM

Products

RituximabEtoposideCarboplatinIfosfamide

Source

Kewalramani, Blood 2004

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.